

Supplemental Table 1. Impact of SIC Service Implementation on Key Outcomes – Logistic Regressions Analyzed by First Admission

Outcome	Pre-SIC ^a	Post-SIC ^b	Coefficient / OR (95% CI) ^c	P Value
	(n = 127 1 st admits)	(n = 122 1 st admits)		
Length of stay, median (IQR), days	5 (3-9)	5 (3-8)	-0.24 (-1.77-1.29) ^d	0.758
Discharged on corticosteroids ^e	87 (71.9%)	74 (64.4%)	0.61 (0.32-1.18) ^f	0.141
Use of non-steroidal immunosuppression	14 (11.0%)	10 (8.2%)	0.93 (0.38-2.31) ^f	0.878
ICI discontinuation for irAE ^g	58 (64.4%)	54 (68.4%)	1.25 (0.62-2.53) ^f	0.526
Died during irAE admission	8 (6.3%)	11 (9.0%)	1.58 (0.60-4.24) ^f	0.361

Abbreviations: SIC, Severe Immunotherapy Complications; OR, odds ratio; CI, confidence interval; IQR, interquartile range.

^a Data are presented as number (percentage) of first admissions, unless otherwise indicated; Pre-SIC date range is 4/2/2016 – 10/2/2017.

^b Data are presented as number (percentage) of first admissions, unless otherwise indicated; Post-SIC date range is 10/3/2017 – 10/24/2018.

^c Data are presented as coefficient (95% CI) for linear regressions (continuous variables) and odds ratio (95% CI) for logistic regressions (categorical variables).

^d Multivariable linear regression with covariates: age, sex, irAE confirmation status, malignancy, ICI class, and primary toxicity type.

^e Excludes patients with thyroid toxicities or diabetes mellitus (given steroids are not indicated) as the irAE. Pre-SIC *n* = 160. Post-SIC *n* = 139.

^f Multivariable logistic regression with covariates: age, sex, irAE confirmation status, malignancy, ICI class, primary toxicity type, and presence of multiple toxicities.

^g Excludes patients with endocrine toxicities (given ICI discontinuation is not indicated) as well as patients who previously discontinued ICI prior to admission or discontinued ICI for any non-irAE reason (disease progression).